Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jun;367(6):553-61.
doi: 10.1007/s00210-003-0751-2. Epub 2003 May 23.

New selective ligands of human cloned melatonin MT1 and MT2 receptors

Affiliations

New selective ligands of human cloned melatonin MT1 and MT2 receptors

Valérie Audinot et al. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun.

Abstract

Melatonin has a key role in the circadian rhythm relay to periphery organs. Melatonin exerts its multiple roles mainly through two seven transmembrane domain, G-coupled receptors, namely MT1 or MT2 receptors. A pharmacological characterization of these human cloned melatonin hMT1 and hMT2 receptors stably expressed in HEK-293 or CHO cells is presented using a 2-[125I]-iodo-melatonin binding assay and a [35S]-GTPgammaS functional assay. Both reference compounds and new chemically diverse ligands were evaluated. Binding affinities at each receptor were found to be comparable on either HEK-293 or CHO cell membranes. Novel non-selective or selective hMT1 and hMT2 ligands are described. The [35S]-GTPgammaS functional assay was used to define the functional activity of these compounds which included partial, full agonist and/or antagonist activity. None of the compounds acted as an inverse agonist. We report new types of selective antagonists, such as S 25567 and S 26131 for MT1 and S 24601 for MT2. These studies brought other new molecular tools such as the selective MT1 agonist, S 24268, as well as the non-selective antagonist, S 22153. Finally, we also discovered S 25150, the most potent melatonin receptor agonist, so far reported in the literature.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Pharmacol. 1996 Jan 18;296(1):33-42 - PubMed
    1. Bioorg Med Chem. 2000 Jan;8(1):105-14 - PubMed
    1. Br J Pharmacol. 1997 Dec;122(7):1299-306 - PubMed
    1. Neuron. 1994 Nov;13(5):1177-85 - PubMed
    1. Br J Pharmacol. 1996 Apr;117(7):1521-9 - PubMed

MeSH terms

LinkOut - more resources